CONFIDENTIAL
Exhibit 10.39.1
FIRST AMENDMENT TO THE MASTER DEVELOPMENT AND
TOLL MANUFACTURING AGREEMENT
BETWEEN ENDO PHARMACEUTICALS INC.
AND NOVARTIS CONSUMER HEALTH, INC.
 
 
 
 
 
The confidential portions of this exhibit have been filed separately with the
Securities and Exchange Commission pursuant to a confidential treatment request
in accordance with Rule 24b-2 of the Securities and Exchange Act of 1934, as
amended. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN ***.

 

--------------------------------------------------------------------------------

 

CONFIDENTIAL
This First Amendment to the Master Development and Toll Manufacturing Agreement
by and between Endo Pharmaceuticals Inc. (“Endo”) and Novartis Consumer Health,
Inc. (“Novartis”) is effective as of February 1, 2003 (this “Amendment”).
WHEREAS, Endo and Novartis entered into an agreement dated May 3, 2001 (the
“Agreement”), whereby Novartis agreed to perform certain Services on behalf of
Endo as set forth therein; and
WHEREAS, Endo and Novartis desire to incorporate additional Products into such
Agreement. Therefore, the Agreement shall be amended as set forth below.
NOW THEREFORE, for good and valuable consideration, the receipt of which is
hereby acknowledged, the parties hereto agree as follows:

1.   Unless set forth herein, the capitalized terms contained in this Amendment
shall have the meanings set forth in the Agreement.   2.   ANNEX A shall be
amended and restated in its entirety with the Annex A attached hereto and made a
part hereof in its entirety.   3.   ANNEX B shall be amended and restated in its
entirety with the Annex B attached hereto and made a part hereof in its
entirety.   4.   ANNEX C shall be amended and restated in its entirety with the
Annex C attached hereto and made a part hereof in its entirety.   5.   Except as
expressly provided herein, all other terms, provisions, conditions and covenants
contained in the Agreement shall remain in full force and effect.

IN WITNESS WHEREOF, Endo and Novartis have executed this Amendment as of the day
and year first written above.

     
ENDO PHARMACEUTICALS INC.
  NOVARTIS CONSUMER HEALTH, INC.
 
   
By: /s/ Peter Lankau
  By: /s/ John McKenna
     Peter Lankau
  Name: John McKenna
     President & Chief Operating Officer
  Title: CFO, Business Unit

2 of 8

--------------------------------------------------------------------------------

 

CONFIDENTIAL
ANNEX A
TO
MASTER DEVELOPMENT AND TOLL MANUFACTURING
AGREEMENT
PRODUCTS

                  NDC     Product Description     Batch Size
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **

3 of 8

--------------------------------------------------------------------------------

 

CONFIDENTIAL

                 
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **

4 of 8

--------------------------------------------------------------------------------

 

CONFIDENTIAL
ANNEX B
MASTER DEVELOPMENT AND TOLL MANUFACTURING
AGREEMENT
PRICING FOR PRODUCTS

                                  Price Per NDC     Description     Bottle
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **

5 of 8

--------------------------------------------------------------------------------

 

CONFIDENTIAL

                 
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **

6 of 8

--------------------------------------------------------------------------------

 

CONFIDENTIAL

                 
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **
***
    * **     * **

7 of 8

--------------------------------------------------------------------------------

 

CONFIDENTIAL
ANNEX C
TO
MASTER DEVELOPMENT AND TOLL MANUFACTURING
AGREEMENT
SPECIFICATIONS
***

8 of 8